Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women

Judith A. Cook, Mardge H. Cohen, Dennis Grey, Lynn Kirstein, Jane Burke, Kathryn Anastos, Herminia Palacio, Jean Richardson, Tracey E. Wilson, Mary Young

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objectives. This study examined longitudinal trends in use of highly active antiretroviral therapy (HAART) among a cohort of HIV-positive participants in the Women's Interagency HIV Study. Methods. Beginning in 1994, 1690 HIV-positive women reported detailed information about their use of antiretroviral therapy at 6-month study visits. Multivariate logistic and Cox regression analyses were used to estimate the likelihood of antiretroviral therapy and HAART use among women with study visits preceding and following HAART availability. Results. Before the availability of HAART, the cohort's likelihood of any antiretroviral therapy use was associated with clinical indicators (CD4 count, viral load, symptom presence) as well as behavioral factors (abstaining from drug and alcohol use, participating in clinical trials). After HAART became commercially available, newly emerging predictors included college education, private insurance, absence of injection drug use history, and not being African American. Conclusions. After the penetration of HAART into this cohort, additional differences emerged between HAART users and nonusers. These findings can inform public health efforts to enhance women's access to the most effective types of therapy.

Original languageEnglish (US)
Pages (from-to)82-87
Number of pages6
JournalAmerican Journal of Public Health
Volume92
Issue number1
StatePublished - Jan 1 2002

Fingerprint

Highly Active Antiretroviral Therapy
HIV
Therapeutics
CD4 Lymphocyte Count
Insurance
Viral Load
Pharmaceutical Preparations
African Americans
Longitudinal Studies
Public Health
Logistic Models
Regression Analysis
Alcohols
Clinical Trials
Education
Injections

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Cook, J. A., Cohen, M. H., Grey, D., Kirstein, L., Burke, J., Anastos, K., ... Young, M. (2002). Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. American Journal of Public Health, 92(1), 82-87.

Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. / Cook, Judith A.; Cohen, Mardge H.; Grey, Dennis; Kirstein, Lynn; Burke, Jane; Anastos, Kathryn; Palacio, Herminia; Richardson, Jean; Wilson, Tracey E.; Young, Mary.

In: American Journal of Public Health, Vol. 92, No. 1, 01.01.2002, p. 82-87.

Research output: Contribution to journalArticle

Cook, JA, Cohen, MH, Grey, D, Kirstein, L, Burke, J, Anastos, K, Palacio, H, Richardson, J, Wilson, TE & Young, M 2002, 'Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women', American Journal of Public Health, vol. 92, no. 1, pp. 82-87.
Cook, Judith A. ; Cohen, Mardge H. ; Grey, Dennis ; Kirstein, Lynn ; Burke, Jane ; Anastos, Kathryn ; Palacio, Herminia ; Richardson, Jean ; Wilson, Tracey E. ; Young, Mary. / Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. In: American Journal of Public Health. 2002 ; Vol. 92, No. 1. pp. 82-87.
@article{167ff26087484e87b7b1be871aa8b3bc,
title = "Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women",
abstract = "Objectives. This study examined longitudinal trends in use of highly active antiretroviral therapy (HAART) among a cohort of HIV-positive participants in the Women's Interagency HIV Study. Methods. Beginning in 1994, 1690 HIV-positive women reported detailed information about their use of antiretroviral therapy at 6-month study visits. Multivariate logistic and Cox regression analyses were used to estimate the likelihood of antiretroviral therapy and HAART use among women with study visits preceding and following HAART availability. Results. Before the availability of HAART, the cohort's likelihood of any antiretroviral therapy use was associated with clinical indicators (CD4 count, viral load, symptom presence) as well as behavioral factors (abstaining from drug and alcohol use, participating in clinical trials). After HAART became commercially available, newly emerging predictors included college education, private insurance, absence of injection drug use history, and not being African American. Conclusions. After the penetration of HAART into this cohort, additional differences emerged between HAART users and nonusers. These findings can inform public health efforts to enhance women's access to the most effective types of therapy.",
author = "Cook, {Judith A.} and Cohen, {Mardge H.} and Dennis Grey and Lynn Kirstein and Jane Burke and Kathryn Anastos and Herminia Palacio and Jean Richardson and Wilson, {Tracey E.} and Mary Young",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "92",
pages = "82--87",
journal = "American Journal of Public Health",
issn = "0090-0036",
publisher = "American Public Health Association Inc.",
number = "1",

}

TY - JOUR

T1 - Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women

AU - Cook, Judith A.

AU - Cohen, Mardge H.

AU - Grey, Dennis

AU - Kirstein, Lynn

AU - Burke, Jane

AU - Anastos, Kathryn

AU - Palacio, Herminia

AU - Richardson, Jean

AU - Wilson, Tracey E.

AU - Young, Mary

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objectives. This study examined longitudinal trends in use of highly active antiretroviral therapy (HAART) among a cohort of HIV-positive participants in the Women's Interagency HIV Study. Methods. Beginning in 1994, 1690 HIV-positive women reported detailed information about their use of antiretroviral therapy at 6-month study visits. Multivariate logistic and Cox regression analyses were used to estimate the likelihood of antiretroviral therapy and HAART use among women with study visits preceding and following HAART availability. Results. Before the availability of HAART, the cohort's likelihood of any antiretroviral therapy use was associated with clinical indicators (CD4 count, viral load, symptom presence) as well as behavioral factors (abstaining from drug and alcohol use, participating in clinical trials). After HAART became commercially available, newly emerging predictors included college education, private insurance, absence of injection drug use history, and not being African American. Conclusions. After the penetration of HAART into this cohort, additional differences emerged between HAART users and nonusers. These findings can inform public health efforts to enhance women's access to the most effective types of therapy.

AB - Objectives. This study examined longitudinal trends in use of highly active antiretroviral therapy (HAART) among a cohort of HIV-positive participants in the Women's Interagency HIV Study. Methods. Beginning in 1994, 1690 HIV-positive women reported detailed information about their use of antiretroviral therapy at 6-month study visits. Multivariate logistic and Cox regression analyses were used to estimate the likelihood of antiretroviral therapy and HAART use among women with study visits preceding and following HAART availability. Results. Before the availability of HAART, the cohort's likelihood of any antiretroviral therapy use was associated with clinical indicators (CD4 count, viral load, symptom presence) as well as behavioral factors (abstaining from drug and alcohol use, participating in clinical trials). After HAART became commercially available, newly emerging predictors included college education, private insurance, absence of injection drug use history, and not being African American. Conclusions. After the penetration of HAART into this cohort, additional differences emerged between HAART users and nonusers. These findings can inform public health efforts to enhance women's access to the most effective types of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036460476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036460476&partnerID=8YFLogxK

M3 - Article

C2 - 11772767

AN - SCOPUS:0036460476

VL - 92

SP - 82

EP - 87

JO - American Journal of Public Health

JF - American Journal of Public Health

SN - 0090-0036

IS - 1

ER -